Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pdl Biopharma Inc (PDLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 440,860
  • Shares Outstanding, K 145,980
  • Annual Sales, $ -85,140 K
  • Annual Income, $ -151,450 K
  • 36-Month Beta 0.26
  • Price/Sales 1.36
  • Price/Cash Flow 3.40
  • Price/Book 0.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.08
  • Number of Estimates 1
  • High Estimate 0.08
  • Low Estimate 0.08
  • Prior Year 0.17
  • Growth Rate Est. (year over year) -52.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.82 +5.32%
on 11/15/18
3.14 -5.41%
on 12/03/18
+0.08 (+2.77%)
since 11/13/18
3-Month
2.25 +32.00%
on 09/17/18
3.14 -5.41%
on 12/03/18
+0.64 (+27.47%)
since 09/13/18
52-Week
2.25 +32.00%
on 09/17/18
3.16 -6.01%
on 03/09/18
+0.02 (+0.68%)
since 12/13/17

Most Recent Stories

More News
PDL BioPharma (PDLI) Up 2.4% Since Last Earnings Report: Can It Continue?

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PDLI : 2.96 (-1.99%)
Report: Exploring Fundamental Drivers Behind Tesla, Nordson, Paycom Software, PDL BioPharma, Corcept Therapeutics, and Willis Towers Watson Public -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tesla, Inc. (NASDAQ:TSLA),...

WLTW : 155.72 (-0.03%)
CORT : 17.43 (+2.23%)
TSLA : 373.23 (+1.81%)
PDLI : 2.96 (-1.99%)
NDSN : 118.27 (+5.53%)
PAYC : 132.52 (-1.54%)
PDL BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference

PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that management will present at the Piper Jaffray Healthcare Conference in New York City. The session will be webcast live and will...

PDLI : 2.96 (-1.99%)
PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up

PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.

PDLI : 2.96 (-1.99%)
GILD : 66.95 (-1.75%)
ALXN : 112.71 (-3.67%)
BIIB : 320.21 (-0.74%)
3 Health Care Stocks Rallying After US Midterms

CORAL GABLES, FL / ACCESSWIRE / November 7,2018 / are rallying after Tuesday's . The Sector SPD Healthcare ETF (XLV) has climbed to highs of $92.24 as of 9:45AM EST. According to Modern Healthcare* the...

PDLI : 2.96 (-1.99%)
PHGI.CN : 0.920 (-9.80%)
PHGRF : 0.7248 (-3.73%)
PDL BioPharma Reports Third Quarter 2018 Financial Results

PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and nine months ended September 30, 2018 including:

PDLI : 2.96 (-1.99%)
PDL BioPharma to Announce Third Quarter Financial Results on November 6, 2018

PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter financial results for the period ended September 30, 2018, on Tuesday, November 6, 2018,...

PDLI : 2.96 (-1.99%)
Sidley Welcomes Life Sciences Licensing Partner Tom Duley in San Francisco

Sidley Austin LLP announced today that Tom Duley has joined the firm as a partner in its global Life Sciences practice. Mr. Duley has extensive experience advising international and...

PDLI : 2.96 (-1.99%)
PDL BioPharma Names Edward Imbrogno Vice President of Finance

PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces the appointment of Edward Imbrogno as Vice President of Finance, a new position. Mr. Imbrogno brings to PDL more than 30 years of public accounting...

PDLI : 2.96 (-1.99%)
PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin, PDL's chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New...

PDLI : 2.96 (-1.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade PDLI with:

Business Summary

Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital...

See More

Key Turning Points

2nd Resistance Point 3.09
1st Resistance Point 3.06
Last Price 2.96
1st Support Level 2.97
2nd Support Level 2.91

See More

52-Week High 3.16
Last Price 2.96
Fibonacci 61.8% 2.81
Fibonacci 50% 2.70
Fibonacci 38.2% 2.60
52-Week Low 2.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar